An End-to-End Enabler of Biologic Innovation

In an increasingly complex industry, Catalent supports biopharma partners by simplifying the inherent intricacies of biologics development. With integrated capabilities spanning drug substance, drug product, and bioanalytics along with deep scientific, regulatory, and operational expertise, Catalent helps customers anticipate challenges and deliver life-changing therapies to patients. In this interview, David McErlane, Group President of Biologics at Catalent, shares his insights on current industry challenges, as well as delivering value beyond technical capabilities.

Learning Objectives:

• Learn how integrated services across the biologics value chain can reduce complexity and risk for biopharma companies.
• Understand the importance of early collaboration, scale-up strategy, and regulatory expertise in accelerating biologics development.
• Explore how Catalent’s scientific depth and operational excellence enable faster problem-solving and greater confidence in advancing therapies to patients.